JP2016503406A5 - - Google Patents

Info

Publication number

JP2016503406A5

JP2016503406A5 JP2015540853A JP2015540853A JP2016503406A5 JP 2016503406 A5 JP2016503406 A5 JP 2016503406A5 JP 2015540853 A JP2015540853 A JP 2015540853A JP 2015540853 A JP2015540853 A JP 2015540853A JP 2016503406 A5 JP2016503406 A5 JP 2016503406A5

Authority

JP

Japan

Prior art keywords

bremeranotide

composition

buremeranochido

pharmaceutically acceptable

aqueous solution

Prior art date

2013-11-05

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 239000000203 mixture Substances 0.000 claims 35
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 16
• 239000007864 aqueous solution Substances 0.000 claims 13
• 150000003839 salts Chemical class 0.000 claims 13
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 12
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 12
• 238000009472 formulation Methods 0.000 claims 11
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 8
• 235000011187 glycerol Nutrition 0.000 claims 8
• 239000003795 chemical substances by application Substances 0.000 claims 7
• 230000036470 plasma concentration Effects 0.000 claims 7
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 6
• MAYUSRUHXFWITM-GBRHMYBBSA-N (3S,6S,9R,12S,15S,23S)-15-[[(2S)-2-acetamidohexanoyl]amino]-9-benzyl-6-[3-(diaminomethylideneamino)propyl]-12-(1H-imidazol-5-ylmethyl)-3-(1H-indol-3-ylmethyl)-2,5,8,11,14,17-hexaoxo-1,4,7,10,13,18-hexazacyclotricosane-23-carboxylic acid acetic acid Chemical compound CC(O)=O.CCCC[C@H](NC(C)=O)C(=O)N[C@H]1CC(=O)NCCCC[C@H](NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC1=O)C(O)=O MAYUSRUHXFWITM-GBRHMYBBSA-N 0.000 claims 5
• 206010057671 Female sexual dysfunction Diseases 0.000 claims 5
• 238000010254 subcutaneous injection Methods 0.000 claims 5
• 239000007929 subcutaneous injection Substances 0.000 claims 5
• 238000000034 method Methods 0.000 claims 4
• FFHBJDQSGDNCIV-MFVUMRCOSA-N bremelanotide Chemical compound C([C@@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCNC(=O)C[C@@H](C(N[C@@H](CC=2NC=NC=2)C(=O)N1)=O)NC(=O)[C@@H](NC(C)=O)CCCC)C(O)=O)C1=CC=CC=C1 FFHBJDQSGDNCIV-MFVUMRCOSA-N 0.000 claims 3
• 229950000740 bremelanotide Drugs 0.000 claims 3
• 108010072543 bremelanotide Proteins 0.000 claims 3
• 230000000694 effects Effects 0.000 claims 3
• 206010019233 Headaches Diseases 0.000 claims 1
• 206010020772 Hypertension Diseases 0.000 claims 1
• 206010028813 Nausea Diseases 0.000 claims 1
• 201000001880 Sexual dysfunction Diseases 0.000 claims 1
• 206010047700 Vomiting Diseases 0.000 claims 1
• 150000001242 acetic acid derivatives Chemical class 0.000 claims 1
• 239000013543 active substance Substances 0.000 claims 1
• 230000035487 diastolic blood pressure Effects 0.000 claims 1
• 239000003814 drug Substances 0.000 claims 1
• 229940079593 drug Drugs 0.000 claims 1
• 238000012377 drug delivery Methods 0.000 claims 1
• 238000011010 flushing procedure Methods 0.000 claims 1
• 231100000869 headache Toxicity 0.000 claims 1
• 238000002347 injection Methods 0.000 claims 1
• 239000007924 injection Substances 0.000 claims 1
• 238000004519 manufacturing process Methods 0.000 claims 1
• 230000008693 nausea Effects 0.000 claims 1
• 229940071643 prefilled syringe Drugs 0.000 claims 1
• 238000002360 preparation method Methods 0.000 claims 1
• 231100000872 sexual dysfunction Toxicity 0.000 claims 1
• 230000001568 sexual effect Effects 0.000 claims 1
• 230000035488 systolic blood pressure Effects 0.000 claims 1
• 230000008673 vomiting Effects 0.000 claims 1